24/7
Buzz
Startups
VC
AI
DefenseTech
Opinions
Events
Promising Startups 2026
2026 VC Survey
Boarding Pass
CTalk
BiblioTech
Corporate
Appointments
Tech Gateways
HR - The Next Leap
Ctech Testimonials
Projects
About
Newsletter
Contact us
Facebook
Twitter
ACCESSIBILITY
by
Homepage
Compugen
Tags search
HOME
24/7
buzz
STARTUPS
VC
AI
DefenseTech
OPINIONS
EVENTS
Projects
ABOUT
teram of use
Privacy Policy
NEWSLETTER
SEARCH
CONTACT US
ACCESSIBILITY
24/7
Headlines
22:27
Five months old, Noetive raises $41 million Seed to build AI for the physical economy
20:39
The man who helped build Palo Alto’s Cortex is leaving the company
20:20
Wiz founders Rappaport and Costica add television to their post-exit portfolio with $120 million Reshet 13 deal
17:12
Israel’s tech exports hit a record but foreign owners are claiming more of the gains
More stories
Buzz
Most popular
Daily
Weekly
1
How an Israeli engineer went from Rafael to iPhone Portrait Mode and a $300 million OpenAI exit
2
Oracle is expanding layoffs but its new CFO says “don’t do more with less”
3
The ThinkPad X13 is almost boring, and that’s exactly the point
4
Buildots raises $130 million at nearly $1 billion valuation as AI boom drives data center construction
5
Former Mossad chief Yossi Cohen joins Israeli quantum tech company Quantum X Labs
More news
Compugen
5 stories about Compugen
Compugen shares soar on massive deal with Gilead, worth up to $848 million
19.12.23
|
Sophie Shulman
The Israeli company utilizes its broadly applicable predictive computational discovery capabilities to identify new drug targets and biological pathways for developing novel cancer immunotherapies
Compugen Falls 17% on Employee Cuts Announcement
27.02.19
|
Lilach Baumer
The Nasdaq-listed cancer immunotherapy company published its fourth quarter and full year results for 2018 Tuesday
Bristol-Myers Squibb Invests $12 Million in Israeli Immunotherapy Company Compugen
12.10.18
|
Dror Reich
The investment is part of a clinical trial collaboration for a treatment that combines Compugen’s investigational antibody with an immune checkpoint inhibitor from Bristol-Myers Squibb
Biotech Company Compugen Down on Nasdaq Following $21 Million Direct Offering
17.06.18
|
Dror Reich
The Israel-based cancer immunotherapy company intends to use the proceedings for product development
AstraZeneca Signs Deal with Cancer Immunotherapy Company Compugen
03.04.18
|
Lilach Baumer
The deal has the potential to be worth over $200 million for Nasdaq-listed Compugen